Pharmaceutical Technology

MAY 4, 2023

The US Food and Drug Administration (FDA) approved Kamada’s application to manufacture Cytogam (cytomegalovirus immune globulin intravenous [human]) at its facility located in Beit Kama, Israel. The regulatory approval represents the completion of the Cytogam technology transfer process from CSL Behring, its previous manufacturer.

FDA Approval 130

FDA Approval Manufacturing Production Protein 130

Pharmaceutical Technology

SEPTEMBER 14, 2022

API peptides and proteins-based drugs have gained much attention in the past decade. The increasing demand for API peptide products is in turn increasing the demand for peptide API manufacturers who also offer contract marketing services. Discover the top API protein and peptide companies in contract marketing.

Protein 100

Protein Marketing Manufacturing Reagent 100

Pharmaceutical Technology

MAY 17, 2023

WuXi Biologics and InflaRx have entered a manufacturing partnership for advancing Gohibic (vilobelimab) to treat certain critically ill Covid-19 patients. Under the collaboration, WuXi Biologics will be responsible for providing cGMP manufacturing of Gohibic.

Manufacturing 130

Manufacturing Immune Response Protein Antibody 130

XTalks

OCTOBER 27, 2020

One such fusion beverage is high-protein iced tea – a functional, refreshing beverage that has the potential to be the next big beverage trend. As an ingredient, whey protein comes with some challenges. It’s not as simple as adding protein powder to iced tea, otherwise everyone would be doing it. This is where iced tea comes in.

Protein 105

Protein Marketing Containment Manufacturing 105

XTalks

JULY 26, 2023

Brevel , an Israeli startup specializing in the conversion of microalgae into alternative proteins, recently secured $18.5 The Tel Aviv-based startup will use the new funding to deliver an alternative protein source that is neutral in taste, highly functional, remarkably sustainable and accessible to the broader food industry.

Protein 97

Protein Production Cosmetics Marketing 97

pharmaphorum

AUGUST 7, 2020

Pfizer has signed a multi-year agreement with Gilead to manufacture and supply the COVID-19 antiviral remdesivir, which is also being tested in combination with other drugs in an effort to fight the pandemic. Pfizer will provide contract manufacturing services at its facility in McPherson, Kansas, to supply the drug to Gilead.

Manufacturing 119

Manufacturing Contract Manufacturing Protein Allergies 119

Bio Pharma Dive

SEPTEMBER 23, 2024

The company’s technology, which enables it to target viral proteins in their “prefusion” shape and skip a manufacturing step, could lead to vaccines that are more potent and easier to produce, said CEO Emmanuel Hanon.

Vaccine 157

Vaccine Vaccination Protein Manufacturing 157

Pharmaceutical Technology

JUNE 24, 2022

The protein-based vaccine is engineered from the genetic sequence of the SARS-CoV-2 virus’ initial strain. Developed utilising Novavax’s recombinant nanoparticle technology to generate antigen obtained from the coronavirus spike (S) protein, the vaccine is also formulated with the company’s saponin-based Matrix-M adjuvant.

Vaccine 263

Vaccine Vaccination Clinical Trials Clinical Trials 263

pharmaphorum

NOVEMBER 2, 2021

In only its second year of operations, Cambridge, UK startup Dunad Therapeutics has already attracted a big pharma partner for its protein degradation platform. If it exercises its option, Novartis will assume responsibility for future development, manufacturing and global commercialisation of therapeutics arising from the alliance.

Protein 98

Protein Licensing Licensing Drugs 98

Bio Pharma Dive

DECEMBER 4, 2024

Novo will pay $200 million to gain control of the protein manufacturing factory. Elsewhere, Roivant dropped a drug program and Takeda acquired a blood disease therapy.

Licensing 144

Licensing Licensing Drugs Protein 144

XTalks

MARCH 26, 2025

In 2025, new initial public offerings (IPOs) are emerging across packaged foods, alternative proteins and tech-enabled food solutions, signaling that scientific investment is becoming a key competitive differentiator. For 2025, Smithfield projects an adjusted operating profit of up to $1.3

Packaging 105

Packaging Packaging Protein Production 105

Pharmaceutical Technology

JUNE 29, 2022

For hundreds of years, we have found myriad uses for microbial enzymes in manufacturing – from food, drink, and household products to a range of industrial applications. The enzymes must be manufactured under cGMP conditions – completely free of animal-derived ingredients.”. Developing best-in-class speciality enzymes.

Drugs 295

Drugs Gene Therapy Production Manufacturing 295

Pharmaceutical Technology

JUNE 6, 2023

Oragenics has secured funding from the Canadian bioresearch consortium CQDM to develop a variant-agnostic protein antigen for use in its Covid-19 intranasal vaccine. Using the advanced manufacturing platform of NRC, these vaccine antigens are expected to be quickly deployable in next-generation vaccine formulations.

Vaccine 231

Vaccine Vaccination Development Manufacturing 231

XTalks

MARCH 31, 2023

By growing high quality crystal structures of protein-based therapeutics under microgravity, researchers can gain better insights into their complex structures and stability. The proteins will be analyzed back on Earth using techniques such as X-ray diffraction and compared with crystals from the same biologics grown on Earth.

Protein 97

Protein Research Development Manufacturing 97

World of DTC Marketing

DECEMBER 29, 2020

Both the Pfizer and Moderna vaccines copied RNA sequence from the virus genome and found a way to manufacture it at scale with high-level processes and quality control. First, a novel approach was used that didn’t require traditional vaccine production in cell cultures or eggs. 1455NO-HEALTH-CORONAVIRUS_VACCINES_PFIZER_O_.

Vaccine 307

Vaccine Vaccination Development Clinical Trials 307

Scienmag

NOVEMBER 19, 2020

Credit: Meditech Gloves Cranfield University researchers in partnership with Meditech Gloves, one of the leading manufacturers of high-quality examination and surgical gloves, have shown how energy savings can be made with the development of more sustainable, biodegradable, protein-free, natural rubber gloves.

Manufacturing 82

Manufacturing Research Protein Development 82

XTalks

NOVEMBER 23, 2021

Canadian pharma and biotech contract development and manufacturing organization (CDMO) Biovectra has announced plans for building one of the first state-of-the-art mRNA vaccine and biomanufacturing facilities in Canada. This left the country without production capabilities for large-scale manufacturing of COVID-19 vaccines.

Manufacturing 98

Manufacturing Vaccine Vaccination Drugs 98

Fierce Pharma

NOVEMBER 8, 2024

With biomanufacturing often a limiting factor for drug developers, Canada’s Future Fields is heralding its bug-based approach to protein production as a potential salve. With biomanufacturing often a limiting factor for drug developers, Canada’s Future Fields is heralding its bug-based approach to protein production as a potential salve.

Protein 72

Protein Production Manufacturing Development 72

BioPharma Reporter

MAY 5, 2022

ExcellGene SA, a Swiss biologics focused CDMO, has established a collaboration agreement with German biological cell instrument developer, Cytena.

Protein 98

Protein Manufacturing Development 98

Pharmaceutical Technology

SEPTEMBER 5, 2022

The company has presently attained steady manufacturing of several innovative vaccines and set up a supply chain worldwide to increase accessibility to quality vaccine products for people globally.

Vaccine 264

Vaccine Vaccination Genetic Engineering Clinical Trials 264

Pharmaceutical Technology

DECEMBER 8, 2022

Under the prior deal, Daiichi Sankyo acquired exclusive rights for the development, manufacturing and commercialisation of Yescarta in Japan. Regulators in Japan have granted approval for the manufacturing plant of Kite in El Segundo, California, US, to produce Yescarta for the Japanese market.

Licensing 305

Licensing Licensing Gene Therapy Gene 305

Scienmag

MARCH 4, 2021

Scientists have known for decades that biological cells manufacture tiny, round structures called extracellular vesicles. However, their pivotal roles […].

Protein 95

Protein RNA Scientist Manufacturing 95

Pharmaceutical Technology

MAY 11, 2023

Bayer has entered a strategic collaboration agreement with biotechnology company Bicycle Therapeutics to discover, develop, manufacture and commercialise Bicycle’s radioconjugates for a number of oncology targets. Bicyclic peptides feature amino acids that can be manufactured synthetically.

Development 162

Development Manufacturing Protein Clinical Development 162

Pharma Mirror

OCTOBER 6, 2021

The rising need for early diagnosis of chronic diseases, coupled with growing demand for drugs which work better and have fewer side effects, is largely responsible for the growth of the protein A resin market. Chromatography requires an antibody to bind to a protein A resin.

Research 130

Research Protein Antibody Manufacturing 130

XTalks

SEPTEMBER 27, 2023

EQUII, a food tech startup renowned for its protein bread that focuses on high complete protein and low carbs, is expanding its product line. This new range, which debuted at Expo East last week, includes Plain and Multigrain protein bread, delivering consumers a blend of nutrition without compromising on flavor.

Protein 59

Protein Branding Containment Production 59

Pharmaceutical Technology

MAY 25, 2023

The technology platforms include the Life Edit gene editing platform, an RNA, cell, protein, vector engineering and induced pluripotent stem cells (iPSCs) platform. ElevateBio intends to use the funds to advance its genetic medicine current good manufacturing practice (cGMP) and process development business, BaseCamp.

Gene Therapy 243

Gene Therapy Gene Gene Editing Development 243

XTalks

JANUARY 7, 2025

Symvess is a one-time, single-use, acellular tissue-engineered vessel (ATEV) composed of human extracellular matrix proteins. Manufactured using vascular smooth muscle cells derived from human aortic tissue, Symvess offers a novel solution for patients with traumatic vascular injuries.

FDA Approval 105

FDA Approval Engineer Clinical Trials Clinical Trials 105

BioSpace

JULY 30, 2024

The advantages of using circular RNAs—including increased durability, enhanced protein expression, and substantially lower manufacturing costs compared to linear mRNAs—have driven a spate of investment in this technology.

RNA 100

RNA Protein Manufacturing 100

Pharma Mirror

JUNE 12, 2021

According to Bioplan Associates, single-use bioprocessing technologies now dominate the pre-commercial manufacturing space. However, Alfa Laval states many companies have not been able to make the transition to ‘full-single-use’ when harvesting proteins due to the lack of a single-use disc-stack centrifuge.

Manufacturing 130

Manufacturing Protein 130

Pharmaceutical Technology

AUGUST 17, 2022

A vaccine called Lymerix , then manufactured by SmithKline Beecham, was approved in the US in 1998 but was quickly withdrawn in 2002 due to insufficient custo mer demand. However, advances in research allowed for the identification of outer surface protein A (OspA) of the bacteria as a target for vaccines.

Vaccine 299

Vaccine Vaccination Bacteria Protein 299

XTalks

SEPTEMBER 8, 2020

Albany Molecular Research Inc (AMRI), a global provider of advanced drug development and manufacturing solutions, announced that they have signed a supply agreement with AstraZeneca. The company has signed on to help manufacture AstraZeneca’s COVID-19 vaccine candidate, AZD1222, intended to protect against the SARS-CoV-2 novel coronavirus.

Manufacturing 83

Manufacturing Vaccine Vaccination Allergies 83

Pharmaceutical Technology

JANUARY 19, 2023

Nuvaxovid is a protein-based vaccine created from the genetic sequence of the initial SARS-CoV-2 virus strain. The expanded manufacturing and marketing approval was based on the data obtained from the Phase II trial, conducted in Australia and the US; a separate Phase II trial held in South Africa; and the UK-sponsored COV-BOOST trial.

Vaccine 147

Vaccine Vaccination Immune Response Protein 147

Pfizer

JULY 26, 2022

Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design. Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design. deliesschef. Tue, 07/26/2022 - 17:41.

Vaccine 111

Vaccine Vaccination Protein Immune Response 111

BioPharma Reporter

JANUARY 24, 2023

CDMO AGC Biologics will produce Tzield (teplizumab-mzwv), a recently-approved T1D treatment from Provention Bio, at its Seattle protein biologics manufacturing site.

Production 97

Production Protein Manufacturing 97

Pharmaceutical Technology

APRIL 28, 2023

The company undertook several initiatives recently to expand its business through new partnerships, expansion of existing relationships, and investment in manufacturing capacity. Initially centered on Librela®, this agreement paves the way for developing and manufacturing other molecules in the coming years. until 2026.

Manufacturing 130

Manufacturing Antibody Clinical Supply Protein 130

BioPharma Reporter

SEPTEMBER 20, 2023

AGC Biologics is a global contract development manufacturing organization (CDMO) providing development and manufacturing services for protein-based biologics and advanced therapies.

Manufacturing 52

Manufacturing Protein Development 52

BioPharma Reporter

SEPTEMBER 20, 2023

AGC Biologics is a global contract development manufacturing organization (CDMO) providing development and manufacturing services for protein-based biologics and advanced therapies.

Manufacturing 52

Manufacturing Protein Development 52